Arlington Partners LLC Buys 10,382 Shares of Bristol Myers Squibb Company $BMY

Arlington Partners LLC grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 10.9% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 105,711 shares of the biopharmaceutical company’s stock after buying an additional 10,382 shares during the period. Arlington Partners LLC’s holdings in Bristol Myers Squibb were worth $4,768,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in BMY. Gibraltar Capital Management Inc. raised its stake in Bristol Myers Squibb by 4.8% during the 3rd quarter. Gibraltar Capital Management Inc. now owns 127,275 shares of the biopharmaceutical company’s stock worth $5,740,000 after buying an additional 5,811 shares during the period. MBA Advisors LLC grew its position in shares of Bristol Myers Squibb by 4.8% in the 3rd quarter. MBA Advisors LLC now owns 7,091 shares of the biopharmaceutical company’s stock valued at $320,000 after acquiring an additional 325 shares during the period. Nwam LLC lifted its holdings in Bristol Myers Squibb by 15.4% during the 3rd quarter. Nwam LLC now owns 11,999 shares of the biopharmaceutical company’s stock valued at $534,000 after purchasing an additional 1,603 shares during the last quarter. Campbell & CO Investment Adviser LLC boosted its holdings in shares of Bristol Myers Squibb by 199.4% during the third quarter. Campbell & CO Investment Adviser LLC now owns 128,750 shares of the biopharmaceutical company’s stock worth $5,807,000 after acquiring an additional 85,752 shares during the period. Finally, Kerusso Capital Management LLC grew its stake in shares of Bristol Myers Squibb by 206.5% in the third quarter. Kerusso Capital Management LLC now owns 54,539 shares of the biopharmaceutical company’s stock valued at $2,460,000 after acquiring an additional 36,742 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Down 2.3%

Shares of BMY opened at $55.30 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The stock has a market cap of $112.58 billion, a PE ratio of 18.68, a P/E/G ratio of 9.38 and a beta of 0.29. The business’s 50-day moving average price is $51.91 and its 200-day moving average price is $48.13.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. During the same period in the previous year, the business earned $1.80 earnings per share. The firm’s revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be paid a $0.63 dividend. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date of this dividend is Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. Bristol Myers Squibb’s dividend payout ratio is currently 85.14%.

Analysts Set New Price Targets

BMY has been the topic of a number of recent analyst reports. UBS Group raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price target for the company from $46.00 to $65.00 in a research note on Wednesday, January 7th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Leerink Partners lifted their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday. HSBC restated a “hold” rating and set a $53.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Finally, Morgan Stanley restated an “underweight” rating and set a $37.00 price objective (up from $36.00) on shares of Bristol Myers Squibb in a research note on Friday, December 12th. Seven research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $56.86.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.